Indications for Venetoclax

Venetoclax/Venetoclax (Venetoclax) is a targeted therapy drug mainly used to treat specific types of hematological malignancies, especially B cell lymphoma and chronic lymphocytic leukemia (CLL). The following are the main indications for Venetoclax/Venetoclax:

Chronic lymphocytic leukemia (CLL): Venetoclax/Venetoclax is approved for the treatment of refractory or relapsed CLL, especially in patients who have shown disease progression despite at least one line of therapy. CLL is a B lymphocyte-derived leukemia, and venetoclax/venetoclax induces leukemia cell apoptosis by inhibiting BCL-2 protein, thereby effectively controlling the progression of the disease.

Chronic lymphocytic leukemia-associated small lymphocytic lymphoma (SLL): SLL is a lymphoma closely related to CLL, Veneclat/Venetoclax is also approved for the treatment ofSLL, particularly in patients who have received at least one line of therapy and have shown disease progression.

BCL-2overexpressing non-Hodgkin lymphoma: In addition to CLL and SLL, venetoclax is also used to treat non-Hodgkin lymphoma that overexpresses BCL-2. In these types of lymphomas, overexpression of BCL-2 renders cancer cells resistant to apoptosis, whereas Venetoclax/Venetoclax’s mechanism of action is to promote cancer cells to undergo apoptosis by inhibitingBCL-2 protein.

Venetoclax/Venetoclax has been launched in China and has been included in medical insurance, and patients can purchase it domestically. Specifications: 100mg*14tablets and the price is around 5,000yuan. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The Turkish version of Venetoclax/Venetoclaxoriginal drug on the market overseas, specification: 100mg*112 tablets, costs about 10,000 per box. Foreign generic drugs are relatively cheaper. For example, the generic drugs sold in Laos and Bangladesh are priced at about more than 4,000 yuan for 100mg*120 tablets. The ingredients of original drugs and generic drugs are basically the same.